Status:
COMPLETED
Effects of Delta-9-THC and Iomazenil in Healthy Humans
Lead Sponsor:
Yale University
Conditions:
Schizophrenia
Mental Disorders
Eligibility:
MALE
18-55 years
Phase:
EARLY_PHASE1
Brief Summary
The study aims to examine the combined effects of delta-9-tetrahydrocannabinol (∆-9-THC or THC) and iomazenil on thinking, perception, mood, memory, attention, and electrical activity of the brain (EE...
Eligibility Criteria
Inclusion
- Exposed to cannabis at least once in their lifetime
Exclusion
- Cannabis naïve
- History of hearing deficit
Key Trial Info
Start Date :
February 11 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 22 2013
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00982982
Start Date
February 11 2009
End Date
February 22 2013
Last Update
December 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Connecticut Healthcare System
West Haven, Connecticut, United States, 06516